The Spanish company will use the funding to accelerate the clinical transition of its LiverAce Combo assay for drug-induced liver injury assessment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback